Factor VIII gene variants and inhibitor risk in African American hemophilia A patients

Blood

Volumn 126, Issue 7, 2015, Pages 895-904

  Gunasekera, Devi ^a,b   Ettinger, Ruth A ^b   Fletcher, Shelley Nakaya ^b   James, Eddie A ^c   Liu, Maochang ^b   Barrett, John C ^d   Withycombe, Janice ^e   Matthews, Dana C ^f   Epstein, Melinda S ^g   Hughes, Richard J ^g   Pratt, Kathleen P ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e Palmetto Richland Memorial Hospital   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; HLA DR15 ANTIGEN; HLA DRB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; AUTOANTIBODY; F8 PROTEIN, HUMAN; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; PROTEIN BINDING;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; BLOOD TRANSFUSION; CAUCASIAN; CD4+ T LYMPHOCYTE; CHILD; EPITOPE MAPPING; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HEMOPHILIA A; HUMAN; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOLECULAR RECOGNITION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BLOOD; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOLECULAR GENETICS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; EPITOPE MAPPING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR VIII; GENETIC VARIATION; HAPLOTYPES; HEMOPHILIA A; HLA-DRB1 CHAINS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RISK FACTORS; YOUNG ADULT;

EID: 84940089438     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599365     Document Type: Article

References (47)

1. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost. 2004;2(7):1082-1095.
2. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922-2934.
3. Peerlinck K, Jacquemin M. Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia. 2010;16(suppl 5):100-106.
4. Gouw SC, van den Berg HM, Fischer K, et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055.
5. Kempton CL, Soucie JM, Miller CH, et al. In nonsevere hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010;8(10):2224-2231.
6. Jacquemin M, Vantomme V, Buhot C, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood. 2003;101(4):1351-1358.
7. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost. 2007;5(12):2399-2407.
8. James EA, van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost. 2011;9(4):689-699.
9. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4(1):68.
10. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia. 2011;17(3):483-489.
11. Ragni MV, Ojeifo O, Feng J, et al Hemophilia Inhibitor Study. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia. 2009;15(5):1074-1082.
12. Boguski MS, Lowe TM, Tolstoshev CM. dbEST - database for "expressed sequence tags". Nat Genet. 1993;4(4):332-333.
13. Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood. 2007;109(9):3713-3724.
14. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618-1627.
15. van Haren SD, Wroblewska A, Fischer K, Voorberg J, Herczenik E. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Rev. 2012;26(1):43-49.
16. van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics. 2011;10(6):M110.002246.
17. van Haren SD, Wroblewska A, Herczenik E, et al. Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII. PLoS ONE. 2013;8(11):e80239.
18. Wroblewska A, Reipert BM, Pratt KP, Voorberg J. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost. 2013;11(1):47-55.
19. Pratt KP, Thompson AR. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin Rev Allergy Immunol. 2009;37(2):80-95.
20. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol. 2007;68(9):779-788.
21. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(12):1236-1237.
22. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S. NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res. 2010;6:9.
23. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 1999;17(6):555-561.
24. Novak EJ, Liu AW, Gebe JA, et al. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J Immunol. 2001;166(11):6665-6670.
25. James EA, Bui J, Berger D, Huston L, Roti M, Kwok WW. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol. 2007;19(11):1291-1301.
26. Kwok WW, Gebe JA, Liu A, et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol. 2001;22(11):583-588.
27. Miller CH, Benson J, Ellingsen D, et al Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375-382.
28. Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014;20(5):687-692.
29. Schwarz J, Astermark J, Menius ED, et al Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 2013;19(1):113-118.
30. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2):238-242.
31. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost. 2005;3(8):1676-1681.
32. Gouw SC, Fijnvandraat K. Unraveling the genetics of inhibitors in hemophilia. Blood. 2013;121(8):1250-1251.
33. Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost. 2013;39(7):740-751.
34. Astermark J, Donfield SM, Gomperts ED, et al Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 2013;121(8):1446-1454.
35. DiMichele DM. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication. Pediatr Blood Cancer. 2013;60(suppl 1):S30-S33.
36. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia. 2011;17(4):641-649.
37. Ghosh K, Shetty S. Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol. 2009;37(2):58-66.
38. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35(8):723-734.
39. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 2011;39(database issue):D1171-D1176.
40. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood. 2009;114(7):1423-1428.
41. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia. 2010;16(102):44-55.
42. Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93(7):2267-2273.
43. Thompson AR, Murphy ME, Liu M, et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood. 1997;90(5):1902-1910.
44. van den Brink EN, Timmermans SM, Turenhout EA, et al. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593 - >Cys substitution. Thromb Haemost. 1999;81(5):723-726.
45. Castaman G, Fijnvandraat K. Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. Blood. 2014;124(15):2333-2336.
46. Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost. 2013;109(3):464-470.
47. Eckhardt CL, van Velzen AS, Peters M, et al INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954-1962.